EBS vs VRTX · rev $1.04B vs P/E 30, rev $12.00B
Emergent Biosolutions Inc (EBS) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
EBS currently screens at market cap $416.4M. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the EBS and VRTX stock pages for the full models.
Not investment advice.